» Articles » PMID: 23152586

Lewy Pathology is Not the First Sign of Degeneration in Vulnerable Neurons in Parkinson Disease

Overview
Journal Neurology
Specialty Neurology
Date 2012 Nov 16
PMID 23152586
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine whether evidence of neuronal dysfunction or demise preceded deposition of Lewy pathology in vulnerable neurons in Parkinson disease (PD).

Methods: We examined the extent of nigral dysfunction and degeneration among 63 normal, incidental Lewy body disease (ILBD), and PD cases based on tyrosine hydroxylase (TH) immunoreactivity and neuron densities, respectively. The relationship between these markers and Lewy pathology (LP) burden in the substantia nigra (SN) and Braak PD stage was assessed.

Results: Compared with normal subjects, ILBD cases displayed a significantly higher percentage of TH-negative cells and lower neuronal densities in the SN as early as Braak PD stages 1 and 2, before LP deposition in the nigrostriatal system. ILBD nigral neuron densities were intermediate between normal subjects and PD cases, and TH-negative percentages were higher in ILBD than either normal or PD cases. Furthermore, neuron density and neuronal dysfunction levels remained relatively constant across Braak PD stages in ILBD.

Conclusions: These results suggest that significant neurodegeneration and cellular dysfunction precede LP in the SN, challenging the pathogenic role of LP in PD and the assumption that ILBD always represents preclinical PD.

Citing Articles

Current insights and assumptions on α-synuclein in Lewy body disease.

Leak R, Clark R, Abbas M, Xu F, Brodsky J, Chen J Acta Neuropathol. 2024; 148(1):18.

PMID: 39141121 PMC: 11324801. DOI: 10.1007/s00401-024-02781-3.


Selective dopaminergic neurotoxicity modulated by inherent cell-type specific neurobiology.

Currim F, Tanwar R, Brown-Leung J, Paranjape N, Liu J, Sanders L Neurotoxicology. 2024; 103:266-287.

PMID: 38964509 PMC: 11288778. DOI: 10.1016/j.neuro.2024.06.016.


Nonintuitive Immunogenicity and Plasticity of Alpha-Synuclein Conformers: A Paradigm for Smart Delivery of Neuro-Immunotherapeutics.

Abioye A, Akintade D, Mitchell J, Olorode S, Adejare A Pharmaceutics. 2024; 16(5).

PMID: 38794271 PMC: 11124533. DOI: 10.3390/pharmaceutics16050609.


The role of the brain renin-angiotensin system in Parkinson´s disease.

Labandeira-Garcia J, Labandeira C, Guerra M, Rodriguez-Perez A Transl Neurodegener. 2024; 13(1):22.

PMID: 38622720 PMC: 11017622. DOI: 10.1186/s40035-024-00410-3.


Angiotensin type 1 receptor activation promotes neuronal and glial alpha-synuclein aggregation and transmission.

Lage L, Rodriguez-Perez A, Villar-Cheda B, Labandeira-Garcia J, Dominguez-Meijide A NPJ Parkinsons Dis. 2024; 10(1):37.

PMID: 38368444 PMC: 10874459. DOI: 10.1038/s41531-024-00650-0.


References
1.
Ma S, Rinne J, Collan Y, Roytta M, Rinne U . A quantitative morphometrical study of neuron degeneration in the substantia nigra in Parkinson's disease. J Neurol Sci. 1996; 140(1-2):40-5. DOI: 10.1016/0022-510x(96)00069-x. View

2.
Adler C, Connor D, Hentz J, Sabbagh M, Caviness J, Shill H . Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord. 2010; 25(5):642-6. PMC: 2935627. DOI: 10.1002/mds.22971. View

3.
Hirsch E, Graybiel A, Agid Y . Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature. 1988; 334(6180):345-8. DOI: 10.1038/334345a0. View

4.
Halliday G, McRitchie D, Cartwright H, Pamphlett R, Hely M, Morris J . Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. J Clin Neurosci. 1996; 3(1):52-60. DOI: 10.1016/s0967-5868(96)90083-1. View

5.
Fearnley J, Lees A . Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991; 114 ( Pt 5):2283-301. DOI: 10.1093/brain/114.5.2283. View